Neratinib, a tyrosine kinase inhibitor, is used in trastuzumab-resistant breast cancer treatment as an alternative to block HER2 signaling (Figure 1; Burstein et al., 2010; Iqbal and Iqbal, 2014; Wani et al., 2015). This evidence concerns the gene ERBB2 and breast cancer.